InflaRx (NASDAQ: IFRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00.
InflaRx N.V. (IFRX)
Last inflarx n.v. earnings: 8/14 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
IFRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IFRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IFRX alerts
High impacting InflaRx N.V. news events
Weekly update
A roundup of the hottest topics
IFRX
News
- InflaRx to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswire
- InflaRx (<a href="https://www.marketbeat.com/stocks/NASDAQ/IFRX/price-target/">NASDAQ: IFRX</a>) had its price target lowered by analysts at Raymond James from $15.00 to $7.00.MarketBeat
- InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic UpdateGlobeNewswire
- InflaRx Announces Encouraging Phase III Topline Results From PANAMO Trial Of Vilobelimab In Severe COVID-19 Patients [TheStreet.com]TheStreet.com
- InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 PatientsGlobeNewswire
IFRX
Earnings
- 5/12/22 - Beat
IFRX
Sec Filings
- 5/12/22 - Form 6-K
- 4/28/22 - Form 6-K
- 4/7/22 - Form 6-K
- IFRX's page on the SEC website